Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol-Myers Squibb

This article was originally published in The Gray Sheet

Executive Summary

Ongoing share repurchase program will be doubled from 25 mil. to 50 mil. shares, the firm reports April 6. A total of 21.2 mil. shares already have been bought back under the program, which was implemented in October 1987. "Current market conditions have created an excellent opportunity to strengthen the company through a purchase of its own shares," BMS Chairman and CEO Richard Gelb states in a same-day release.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT000464

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel